On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment. The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”. For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer
The first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany. The main objectives of this […]
Symposium on Sexuality / Women’s Sexual Dysfunction Friday October 20, 2017 Chairpersons: Ali Kubba and Josep Perello Programme: Rossella E. Nappi: Sexual symptoms at menopause: are they all women’s dysfunction? Johannes Bitzer: Sexual health care for cancer patients. Rik HW van Lunsen: The Amsterdam multifacettel approach of sexual pain disorders aiming at restoring sexual pleasure. Herjan J.T. Coelingh Bennink: Improvement of sexual function during pill use by normalising free testosterone levels. For more information please […]
On Wednesday May 24, 2017 Pantarhei sponsored a symposium entitled “Estrogens for breast- and prostate cancer treatment”. Lectures were presented by Herjan Coelingh Bennink (High dose estrogens for breast cancer), Carole Verhoeven (Estetrol for breast cancer) and Yvette Zimmerman (Estetrol for prostate cancer). The session was chaired by Ludwig Kiesel and Cobi Reisman.